GHK-Cu

Identity

Mechanism of action

Plain language

GHK-Cu acts as a signal that tells skin and other tissue cells to ramp up repair and collagen-building activity, partly by delivering copper into cells in a chemically quiet, non-reactive form, and partly by switching a large number of genes involved in tissue remodeling on or off.

Technical

The tripeptide's glycine residue is the primary copper-binding site; copper(II) redox activity is chemically silenced when complexed with GHK, proposed as the basis for non-toxic, targeted copper delivery to cells. In fibroblast culture, GHK-Cu at picomolar-to-nanomolar concentrations has been reported to stimulate synthesis of collagen types I, III, and V, glycosaminoglycans, and decorin. A large-scale gene-expression analysis reported GHK-Cu modulates expression of roughly 4,000 human genes, about 31 percent of genes analyzed in that dataset, upregulating a subset including collagen and DNA-repair genes and downregulating others including some pro-inflammatory signaling genes. This gene-expression breadth is itself a caution flag: a peptide affecting nearly a third of the analyzed genome is not acting through a single, well-isolated pathway, and the functional consequence of many of these individual gene changes in vivo, especially systemically after injection, is proposed and extrapolated rather than directly demonstrated in controlled human studies.

Sources: Pickart L, et, 1980, Maquart FX, Pickart, 1988, Pickart L, Margolina, 2018

What it’s used for

Human trials, not approved for this use

• A randomized, evaluator-blinded, vehicle-controlled 12-week trial in women with photodamaged facial skin (n=71) reported that a GHK-Cu-containing cream and serum increased skin density and thickness and reduced fine-line and wrinkle depth versus vehicle.

  Sources: Leyden JJ, Grove, 2002

• A separate randomized, blinded-evaluator trial of topical GHK-Cu skincare regimens after CO2 laser facial resurfacing found no statistically significant difference in the rate of erythema resolution between GHK-Cu and control regimens, but significantly higher patient-reported satisfaction in the GHK-Cu group.

  Sources: Miller TR, Wagner, 2006

Off-label / community use

• Injectable GHK-Cu is used off-label in longevity, aesthetic, and recovery communities for systemic anti-aging, skin-quality, and wound or injury recovery claims, extrapolating from the topical cosmetic evidence base and from animal injectable data. This is anecdotal, community-driven use without controlled human injectable data.

  Sources: thepeptidecatalog.com. GHK-Cu Topical

Pharmacokinetics

Reconstitution

Worked example

On a U-100 insulin syringe at 25 mg/mL, a 1 mg dose corresponds to approximately 4 units (0.04 mL); a 2 mg dose corresponds to approximately 8 units (0.08 mL).

Sources: Multiple commercial vendor

Storage and post-reconstitution stability

Unopened storage

Vendor sources describe reconstituted GHK-Cu solutions as light-sensitive, since copper complexes are generally photoreactive, and recommend refrigerated storage; no published stability study specific to lyophilized, unreconstituted GHK-Cu was identified.

Post-reconstitution stability – Vendor claim

Described only as similar to other reconstituted peptides, weeks not months; no specific day figure given. Light-sensitive, refrigerated

No citable figure. No published stability study specific to GHK-Cu injectable solution was identified; this qualitative range is vendor guidance, not a validated figure.

Safety

Contraindications

• GHK-Cu, and copper supplementation generally, is contraindicated in individuals with Wilson disease and related genetic copper-metabolism disorders, and should be used with caution and medical supervision in anyone with hepatic disease or on copper-chelation therapy.

  Sources: Agency for Toxic, 2024

Notable risks

• No controlled human safety data exist for injectable or systemic GHK-Cu. Topical human trials reported the cosmetic formulations as generally well tolerated, with no major adverse events highlighted in available summaries, though full adverse-event tables from the primary sources were not independently reviewed.

  Sources: Leyden JJ, Grove, 2002, Miller TR, Wagner, 2006

• GHK-Cu stimulates angiogenesis and modulates matrix metalloproteinase expression, pathways that overlap with those exploited by tumors, and free ionic copper has independently been reported elevated in the serum of several malignancy types and implicated in tumor angiogenesis via HIF-1alpha and VEGF signaling. Whether the chelated, redox-silenced form in GHK-Cu carries the same risk as free ionic copper is unresolved. Countervailing animal and in-vitro evidence exists showing GHK-Cu or related copper-peptide treatment inhibiting tumor growth in some models; the literature is mixed and context-dependent rather than settled in either direction.

  Sources: Copper activates HIF-1alpha/GPER/VEGF, Skin Regenerative and, 2018

• The U.S. tolerable upper intake level for dietary copper in adults is 10,000 mcg per day, based on liver-damage risk, but this applies to oral or dietary intake, not to injected chelated-copper-peptide dosing, and no source establishes a safe systemic copper-loading threshold specific to injected GHK-Cu. Common signs of copper excess reported in the general toxicology literature include nausea, vomiting, diarrhea, and abdominal pain.

  Sources: National Academies /, Agency for Toxic, 2024

Sources

1. Pickart L, et al. Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature (1980)
2. Maquart FX, Pickart L, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex. FEBS Lett (1988)
3. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci (2018)
4. Leyden JJ, Grove GL, Barkovic S, Appa Y. Clinical Evaluation of a Copper Tripeptide Cream and Serum for Photodamaged Skin. J Cosmet Dermatol (2002)
5. Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of Topical Copper Tripeptide Complex on CO2 Laser-Resurfaced Skin. Arch Facial Plast Surg (2006)
6. Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological Profile for Copper (a peer-reviewed systematic literature compilation, not FDA/EMA prescribing information or a Federal Register notice) (2024)
7. National Academies / NCBI Bookshelf. Copper. Dietary Reference Intakes
8. Copper activates HIF-1alpha/GPER/VEGF signalling in cancer cells
9. Skin Regenerative and Anti-Cancer Actions of Copper Peptides. MDPI (Cosmetics) (2018)
10. Multiple commercial vendor and dosing-guide pages (e.g. perfectb.com, thepeptidecatalog.com, dosagepeptide.com), cited only to describe commercially sold vial strengths and vendor-stated reconstitution and dosing convention, not as evidence for any efficacy or safety claim
11. thepeptidecatalog.com. GHK-Cu Topical vs Injectable: 10x Absorption Gap. Commercial source, cited only to document the acknowledged absence of injectable human trial data
12. peptidedosages.com, GHK-Cu 50 mg vial dosage protocol